Drew Weissman

Drew Weissman was born on September 7, 1959, and raised in Lexington, Massachusetts. His parents were both involved in engineering and dentistry, fostering an environment of intellectual curiosity and problem-solving. Weissman developed an early interest in science, particularly in understanding how the body fights disease. He pursued his undergraduate education at Brandeis University, where he earned both a Bachelor of Arts and a Master of Arts degree in 1981, focusing on biochemistry and enzymology.

He then attended the University of Pennsylvania School of Medicine, receiving his MD and PhD in 1987. His doctoral research centered on immunology and the mechanisms by which the immune system recognizes pathogens. Following medical school, Weissman completed his clinical training in internal medicine at Beth Israel Deaconess Medical Center in Boston. Seeking to deepen his research expertise, he secured a prestigious fellowship at the National Institutes of Health (NIH) under the mentorship of Anthony Fauci, then already a leading figure in immunology and infectious diseases. During his years at the NIH in the early 1990s, Weissman studied HIV pathogenesis and vaccine development, experiences that would profoundly shape his later work on mRNA therapeutics.

In 1997, Weissman joined the faculty at the University of Pennsylvania's Perelman School of Medicine, where he established his laboratory focused on vaccines and immunotherapy. His initial research explored dendritic cells—specialized immune cells that act as the body's sentinels, detecting invaders and initiating immune responses. Weissman's goal was to harness dendritic cells to create more effective vaccines, particularly for HIV, which had eluded traditional vaccine strategies.

It was during this period that he encountered Katalin Karikó, a research assistant professor struggling to gain support for her vision of using synthetic mRNA to treat disease. The fundamental challenge they faced was immunogenicity: the body's innate immune system recognized foreign RNA as a viral threat and mounted an inflammatory response that destroyed the RNA and often caused harmful side effects. This was the principal barrier preventing mRNA from becoming a practical therapeutic tool.

Through meticulous experimentation beginning in the late 1990s, Weissman and Karikó discovered that naturally occurring chemical modifications in RNA—specifically, replacing the nucleoside uridine with pseudouridine—rendered the RNA molecules nearly invisible to the immune system's sensors. This breakthrough, published in key papers in 2005 and 2008, demonstrated that modified mRNA could be safely delivered into cells, where it would produce the desired proteins without triggering inflammation. Their work also showed that incorporating modified nucleosides improved the stability and translation efficiency of the RNA.

For years, the significance of this discovery was underappreciated. Funding was limited, and major pharmaceutical companies showed little interest. Weissman and Karikó persisted, refining their methods and exploring applications ranging from protein replacement therapy to vaccine development. They patented their foundational discoveries, licensing the technology to small biotech firms that would eventually become critical players in the mRNA field.

The global COVID-19 pandemic in 2020 suddenly thrust their decades of work into the spotlight. Both Pfizer-BioNTech and Moderna built their highly effective COVID-19 vaccines on the platform Weissman and Karikó had developed. The modified mRNA technology allowed these vaccines to be designed, tested, and manufactured with unprecedented speed, delivering protection to billions of people and demonstrating the real-world power of their scientific insights. Weissman himself contributed directly to pandemic response efforts, advising on vaccine development and continuing his research on improving mRNA delivery and broadening its applications.

Weissman's most celebrated contribution is the co-discovery, with Karikó, that incorporating modified nucleosides into mRNA prevents the innate immune system from recognizing and destroying it. This single insight removed the primary obstacle to therapeutic use of mRNA and opened the door to a new class of medicines. The technique is now foundational to multiple approved vaccines and a growing pipeline of experimental therapies.

Beyond the modification itself, Weissman has advanced understanding of how mRNA is translated within cells, how lipid nanoparticles can efficiently deliver mRNA to target tissues, and how to optimize immune responses triggered by mRNA vaccines. His laboratory has explored mRNA vaccines for a wide array of infectious diseases, including influenza, Zika virus, herpes simplex, and HIV. He has also pursued mRNA-based cancer vaccines designed to train the immune system to recognize and attack tumor cells.

One notable project involves developing a universal influenza vaccine—an mRNA construct that could provide long-lasting protection against multiple strains of flu, eliminating the need for annual vaccination updates. Weissman's team has also worked on mRNA therapies for rare genetic disorders, aiming to replace missing or defective proteins in conditions such as cystic fibrosis and certain metabolic diseases. His research embodies the promise that mRNA can be programmed like software to instruct the body to heal itself.

The Nobel Prize in Physiology or Medicine, awarded jointly to Weissman and Karikó in October 2023, recognized their discoveries as transformative contributions to human health. The Nobel Assembly noted that their work 'fundamentally changed our understanding of how mRNA interacts with our immune system' and enabled the rapid development of vaccines during one of the worst pandemics in modern history.

Prior to the Nobel, Weissman received numerous prestigious honors. In 2021, he and Karikó shared the Lasker-DeBakey Clinical Medical Research Award, often considered a predictor of the Nobel Prize. They also received the Breakthrough Prize in Life Sciences in 2022, which came with significant financial recognition and public celebration of their work. Other accolades include the Princess of Asturias Award for Technical and Scientific Research in 2021, the Paul Ehrlich and Ludwig Darmstaedter Prize in 2022, and election to the National Academy of Sciences.

Weissman has been recognized by his home institution as well, appointed as the Roberts Family Professor of Vaccine Research at Penn Medicine. His contributions have been featured in major media outlets worldwide, and he has become a respected public voice on vaccine science and the future of mRNA medicine.

Drew Weissman's legacy lies in transforming a fragile laboratory molecule into a robust platform that is reshaping medicine. The COVID-19 vaccines alone have been administered billions of times, preventing countless deaths and hospitalizations. But the broader impact is still unfolding. Researchers around the world are now applying the Weissman-Karikó principles to develop therapies for diseases once considered intractable. The speed, adaptability, and precision of mRNA technology promise a future where vaccines and treatments can be tailored to emerging threats and individual patients.

Weissman's work exemplifies the power of persistent, curiosity-driven research. For years, he and Karikó labored in relative obscurity, driven by scientific conviction rather than immediate acclaim. Their story has become a touchstone in discussions about how innovation happens—often slowly, collaboratively, and in the face of skepticism. It also highlights the importance of academic freedom and sustained funding for basic research, whose applications may not be apparent for decades.

Looking forward, Weissman continues to lead one of the world's foremost laboratories in mRNA research. He remains committed to mentoring the next generation of scientists and to ensuring that mRNA therapies reach underserved populations. His vision extends beyond infectious disease to chronic conditions, cancer, and genetic disorders, aiming to fulfill the full therapeutic potential of a technology that began with a conversation by a photocopier and grew into a Nobel Prize-winning revolution in medicine.